Sfoglia per AUTORE
OLIVA S
Collezione AO Cuneo

  

Items : 2

Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial. in EClinicalMedicine / EClinicalMedicine. 2023 Jun 9;60:102017. doi: 10.1016/j.eclinm.2023.102017. eCollection 2023 Jun.

2023
AO Cuneo
AOU Città della Salute di Torino

Fanti S; Tacchetti P; Zucchetta P; Pascarella A; Villanova T; De Cicco G; Patriarca F; Fioritoni F; Priola C; Sgherza N; Grasso M; Versari A; Bertamini L; Gamberi B; Albano D; Zambello R; Racca M; Galli M; Belotti A; D'Agostino M; Rota-Scalabrini D; Capra A; Gay F; Oliva S; Zamagni E; Mancuso K; Barbato S; Boccadoro M; Musto P; et alii...

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. in The Lancet. Haematology / Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.

2020
AOU Città della Salute di Torino
AO Cuneo

Sonneveld P; Boccadoro M; Carvalho S; Spencer A; Palmas A; Cafro AM; Minnema M; Mandigers C; van Marwijk Kooy M; Gimsing P; Mellqvist UH; Waage A; Driessen C; Specchia G; Zander T; Caravita di Toritto T; Durian M; von dem Borne PA; Hajek R; Wu KL; Boersma R; Morelli AM; Aquino S; Ludwig H; Levin MD; Bos G; Pascarella A; Benevolo G; Troia R; et alii...